Exact Mass: 261.1641

Exact Mass Matches: 261.1641

Found 157 metabolites which its exact mass value is equals to given mass value 261.1641, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Metycaine

Piperocaine

C16H23NO2 (261.1729)


C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent

   

Acrifoline

Alkaloid L27

C16H23NO2 (261.1729)


A quinolizidine alkaloid that is lycopodine having a C=C double bond at the 11-position, a keto substituent at the 8-position and the keto group at position 5 replaced by a beta-hydroxy group.

   
   

Bufuralol

2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethan-1-ol

C16H23NO2 (261.1729)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists Bufuralol (Ro 3-4787) is a potent non-selective, orally active β-adrenoreceptor antagonist with partial agonist activity. Bufuralol hydrochloride is a CYP2D6 probe substrate[1][2][3][4].

   

Hexylcaine

1-(cyclohexylamino)propan-2-yl benzoate

C16H23NO2 (261.1729)


Hexylcaine hydrochloride, also called cyclaine (Merck) or osmocaine, is a short-acting local anesthetic. It acts by inhibiting sodium channel conduction. Overdose can lead to headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function. C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent

   

1-(2-aminophenyl)decane-1,3-dione

1-(2-aminophenyl)decane-1,3-dione

C16H23NO2 (261.1729)


   

Beta-hydroxyisovaleroylcarnitine

(3R)-3-[(3-hydroxy-3-methylbutanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO5 (261.1576)


3-Hydroxyisovalerylcarnitine is structual derivative of 3-hydroxyisovaleric acid and carnitine. Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns (PMID: 18088573). Analysis of acylcarnitines by tandem mass spectrometry (MS/MS) has recently been used to screen newborns for organic acidemias and fatty acid oxidation defects (PMID: 7494654, 9216448, 11427446, 12127323, 14578311). These diseases cause the accumulation of acyl-CoA, which is esterified to acylcarnitine by carnitine acyltransferase. Acylcarnitine is then eliminated in the urine, thus acylcarnitine concentration serves as an excellent indicator for these diseases (PMID: 6361812). 3-Hydroxyisovalerylcarnitine (C5OH-I) is an indicator for diagnoses of multiple carboxylase deficiency (MCD), 3-methylcrotonyl-CoA carboxylase deficiency and 3-hydroxy-3-methylglutaryl-CoA lyase deficiency (PMID: 18088573), which are inborn errors of metabolism.

   

hydroxyisovaleroyl carnitine

3-hydroxy-3-[(3-methylbutanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO5 (261.1576)


hydroxyisovaleroyl carnitine is classified as a member of the Acyl carnitines. Acyl carnitines are organic compounds containing a fatty acid with the carboxylic acid attached to carnitine through an ester bond. hydroxyisovaleroyl carnitine is considered to be practically insoluble (in water) and acidic. hydroxyisovaleroyl carnitine is a fatty ester lipid molecule

   

2-Hydroxyisovalerylcarnitine

(3R)-3-{[(2R)-2-hydroxy-3-methylbutanoyl]oxy}-4-(trimethylazaniumyl)butanoic acid

C12H23NO5 (261.1576)


2-Hydroxyisovalerylcarnitine belongs to the class of organic compounds known as acylcarnitines. These are organic compounds containing a fatty acid with the carboxylic acid attached to carnitine through an ester bond. 2-Hydroxyisovalerylcarnitine is an extremely weak basic (i. e. Human blood levels of 2-hydroxyisovalerylcarnitine were reported to be influenced by genetic variants in the gene HLCS which codes for the enzyme holocarboxylase synthetase (PMID: 26401656). Holocarboxylase synthetase deficiency (OMIM: 253270), also called HLCS deficiency, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder caused by a defective holocarboxylase synthetase. Individuals with HLCS deficiency are unable to utilize biotin effectively.

   

(2S,3R)-3-Hydroxy-2-methylbutanoylcarnitine

3-[(3-hydroxy-2-methylbutanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO5 (261.1576)


(2S,3R)-3-Hydroxy-2-methylbutanoylcarnitine is an acylcarnitine. More specifically, it is an (2S,3R)-3-hydroxy-2-methylbutanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2S,3R)-3-Hydroxy-2-methylbutanoylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine (2S,3R)-3-Hydroxy-2-methylbutanoylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxyvalerylcarnitine

3-[(3-hydroxypentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO5 (261.1576)


3-Hydroxyvalerylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxypentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyvalerylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 3-Hydroxyvalerylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular 3-Hydroxyvalerylcarnitine is elevated in the blood or plasma of individuals with 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (PMID: 28583327) and holocarboxylase synthetase deficiency (PMID: 27114915). It is also decreased in the blood or plasma of individuals with psoriasis (PMID: 33391503). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxypentanoylcarnitine

3-[(5-hydroxypentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO5 (261.1576)


5-hydroxypentanoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxypentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-hydroxypentanoylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 5-hydroxypentanoylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular 5-hydroxypentanoylcarnitine is elevated in the blood or plasma of individuals with 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (PMID: 28583327) and holocarboxylase synthetase deficiency (PMID: 27114915). It is also decreased in the blood or plasma of individuals with psoriasis (PMID: 33391503). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Pinacidil pyridine N-oxide

N-cyano-N-(3,3-dimethylbutan-2-yl)-N-(1-hydroxy-1,4-dihydropyridin-4-ylidene)guanidine

C13H19N5O (261.159)


   

Gnidioidine

11,12-Didehydroclavonoline

C16H23NO2 (261.1729)


   

Lycoposerramine C

Lycoposerramine C

C16H23NO2 (261.1729)


   

Lycoposerramine I

Lycoposerramine I

C16H23NO2 (261.1729)


   
   

Lycophlegmine

Lycophlegmine

C16H23NO2 (261.1729)


   

Lycoposerramine K

Lycoposerramine K

C16H23NO2 (261.1729)


   

Anhydroaposerratinine

Anhydroaposerratinine

C16H23NO2 (261.1729)


   

Lycoposerramine H

Lycoposerramine H

C16H23NO2 (261.1729)


   

Isoinundatine

2-Oxolycopecurine 5-ketone

C16H23NO2 (261.1729)


   

Phlegmariurine B

Phlegmariurine B

C16H23NO2 (261.1729)


   

Axisothiocyanate 4

(1R,3aR,7aR)-Octahydro-1-(1-isothiocyanato-2-methyl-1-propenyl)-3a-methyl-7-methylene-1H-indene

C16H23NS (261.1551)


   
   

Phlegmariurine A

Phlegmariurine A

C16H23NO2 (261.1729)


   

5-methylbenzene-1,3-diol

5-methylbenzene-1,3-diol

C16H23NO2 (261.1729)


   
   

Prodine

1,3-diphenyl-1-hexanone

C16H23NO2 (261.1729)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Acetamide, N-[4,5-dimethyl-2-(1-oxohexyl)phenyl]-

Acetamide, N-[4,5-dimethyl-2-(1-oxohexyl)phenyl]-

C16H23NO2 (261.1729)


   

4-Methoxy-alpha-pyrrolidinovalerophenone

4-Methoxy-alpha-pyrrolidinovalerophenone

C16H23NO2 (261.1729)


   

Propylphenidate

Propylphenidate

C16H23NO2 (261.1729)


   

ISOPROPYLPHENIDATE

ISOPROPYLPHENIDATE

C16H23NO2 (261.1729)


   

10-isothiocyanato-4,6-amorphadiene

10-isothiocyanato-4,6-amorphadiene

C16H23NS (261.1551)


   

11alpha-hydroxyfawcettidine

11alpha-hydroxyfawcettidine

C16H23NO2 (261.1729)


   

alpha-5-C-(1,3-dihydroxybutyl)-hyacinthacine A1

alpha-5-C-(1,3-dihydroxybutyl)-hyacinthacine A1

C12H23NO5 (261.1576)


   

3,10-Dioxo-12-methyl-decahydro-1H-8,10b-propano-benzo(ij)chinolin|3,10-Dioxo-12-methyl-decahydro-1H-8,10b-propano-benzochinolin|3,10-Dioxo-12-methyldecahydro-1H-8,10b-propano-benzochinolizin

3,10-Dioxo-12-methyl-decahydro-1H-8,10b-propano-benzo(ij)chinolin|3,10-Dioxo-12-methyl-decahydro-1H-8,10b-propano-benzochinolin|3,10-Dioxo-12-methyldecahydro-1H-8,10b-propano-benzochinolizin

C16H23NO2 (261.1729)


   

Dihydrojoubertiamin|dihydrojoubertiamine

Dihydrojoubertiamin|dihydrojoubertiamine

C16H23NO2 (261.1729)


   
   
   

8-Deoxy-13-dehydroserratinin|8-deoxy-13-dehydroserratinine

8-Deoxy-13-dehydroserratinin|8-deoxy-13-dehydroserratinine

C16H23NO2 (261.1729)


   

lycopoclavamine-A

lycopoclavamine-A

C16H23NO2 (261.1729)


   

(?)-4-(4-methoxyphenyl)-1-piperidin-2-ylbutan-2-one|1-(2-piperidyl)-4-(p-methoxyphenyl)-2-butanone|1-(2-piperidyl)-4-(p-methoxyphenyl)-butanone-2

(?)-4-(4-methoxyphenyl)-1-piperidin-2-ylbutan-2-one|1-(2-piperidyl)-4-(p-methoxyphenyl)-2-butanone|1-(2-piperidyl)-4-(p-methoxyphenyl)-butanone-2

C16H23NO2 (261.1729)


   

12-deoxyhuperzine|12-deoxyhuperzine O

12-deoxyhuperzine|12-deoxyhuperzine O

C16H23NO2 (261.1729)


   

(2E,4E,8E,10E)-N-(2-methylpropyl)-12-oxododeca-2,4,8,10-tetraenemide|Lanyuamide V

(2E,4E,8E,10E)-N-(2-methylpropyl)-12-oxododeca-2,4,8,10-tetraenemide|Lanyuamide V

C16H23NO2 (261.1729)


   

Acanthene B

Acanthene B

C16H23NS (261.1551)


   

SCHEMBL3288749

SCHEMBL3288749

C16H23NO2 (261.1729)


   

Pinacidil-N-Oxide

Pinacidil-N-Oxide

C13H19N5O (261.159)


   

3-Hydroxyisovalerylcarnitine

3-(3-hydroxy-3-methylbutanoyl)oxy-4-(trimethylazaniumyl)butanoate

C12H23O5N1 (261.1576)


3-hydroxyisovalerylcarnitine is an O-acylcarnitine having 3-hydroxyisovaleryl as the acyl substituent. It has a role as a human metabolite. It is functionally related to a 3-hydroxyisovaleric acid. 3-Hydroxyisovalerylcarnitine is a specific amino acid derivative that belongs to the class of compounds known as carnitines. This molecule plays a crucial role in the transport of fatty acids into the mitochondria for oxidation, a key process in energy production. The name "3-Hydroxyisovalerylcarnitine" reflects its chemical structure: it consists of a carnitine moiety attached to a 3-hydroxyisovaleryl group. The term "3-hydroxyisovaleryl" refers to a side chain derived from a pentanoic acid (a five-carbon acid) that contains a hydroxyl group (-OH) bonded to the third carbon atom in the chain. This hydroxyl group is critical for the compound's function and is a distinguishing feature of this particular carnitine derivative. 3-Hydroxyisovalerylcarnitine involved in fatty acid metabolism, characterized by its unique hydroxyisovaleryl substituent attached to the carnitine backbone.

   

CAR 5:0;O

3-[(3-hydroxy-3-methylbutanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO5 (261.1576)


   
   

Piperidine,2-[(2S,4S)-2-ethyl-2-phenyl-1,3-dioxolan-4-yl]-, (2S)-

Piperidine,2-[(2S,4S)-2-ethyl-2-phenyl-1,3-dioxolan-4-yl]-, (2S)-

C16H23NO2 (261.1729)


   

N-tert-Butoxycarbonylserine tert-butyl ester

N-tert-Butoxycarbonylserine tert-butyl ester

C12H23NO5 (261.1576)


   

2-(4-Methoxybenzyl)-1,3,3-triMethylpiperidin-4-one

2-(4-Methoxybenzyl)-1,3,3-triMethylpiperidin-4-one

C16H23NO2 (261.1729)


   

3-(DIETHYLAMINO)PROPYL CINNAMATE

3-(DIETHYLAMINO)PROPYL CINNAMATE

C16H23NO2 (261.1729)


   

(R)-N-BOC-(5-BROMO-2-METHOXYPHENYL)ALANINE

(R)-N-BOC-(5-BROMO-2-METHOXYPHENYL)ALANINE

C12H23NO5 (261.1576)


   

7,7-dimethyl-3-pentyl-6,8-dihydro-1H-quinoline-2,5-dione

7,7-dimethyl-3-pentyl-6,8-dihydro-1H-quinoline-2,5-dione

C16H23NO2 (261.1729)


   

(s)-methyl 4-(boc-(methyl)amino)-5-hydroxypentanoate

(s)-methyl 4-(boc-(methyl)amino)-5-hydroxypentanoate

C12H23NO5 (261.1576)


   

Boc-Ser(tBu)-OH

Boc-Ser(tBu)-OH

C12H23NO5 (261.1576)


   

Ethyl 4-(4,4-dimethyl-1-piperidinyl)benzoate

Ethyl 4-(4,4-dimethyl-1-piperidinyl)benzoate

C16H23NO2 (261.1729)


   

[8-(3-Methylphenyl)-1,4-dioxaspiro[4.5]dec-8-yl]Methylamine

[8-(3-Methylphenyl)-1,4-dioxaspiro[4.5]dec-8-yl]Methylamine

C16H23NO2 (261.1729)


   

Ethyl 1-benzyl-4,4-dimethylpyrrolidine-3-carboxylate

Ethyl 1-benzyl-4,4-dimethylpyrrolidine-3-carboxylate

C16H23NO2 (261.1729)


   

5-FLUORO-3-(3-(PIPERAZIN-1-YL)PROPYL)-1H-INDOLE

5-FLUORO-3-(3-(PIPERAZIN-1-YL)PROPYL)-1H-INDOLE

C15H20FN3 (261.1641)


   

N-BOC-(2R,3S)-2-HYDROXY-3-AMINO-5-METHYLHEXANOIC ACID

N-BOC-(2R,3S)-2-HYDROXY-3-AMINO-5-METHYLHEXANOIC ACID

C12H23NO5 (261.1576)


   

N-CYCLOPROPYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIMIDIN-2-AMINE

N-CYCLOPROPYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIMIDIN-2-AMINE

C13H20BN3O2 (261.1648)


   

Boc-(2S,3R)-3-amino-2-hydroxy-5-methylhexanoic acid

Boc-(2S,3R)-3-amino-2-hydroxy-5-methylhexanoic acid

C12H23NO5 (261.1576)


   

(2S,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-2-HYDROXY-5-METHYLHEXANOIC ACID

(2S,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-2-HYDROXY-5-METHYLHEXANOIC ACID

C12H23NO5 (261.1576)


   

1-Piperidinecarboxylic acid, 4-phenyl-, 1,1-dimethylethyl ester

1-Piperidinecarboxylic acid, 4-phenyl-, 1,1-dimethylethyl ester

C16H23NO2 (261.1729)


   

(8-Benzyl-1-oxa-8-azaspiro[4.5]dec-2-yl)methanol

(8-Benzyl-1-oxa-8-azaspiro[4.5]dec-2-yl)methanol

C16H23NO2 (261.1729)


   
   

(R)-N-(3-((2-AMINOETHYL)AMINO)-3-OXOPROPYL)-2,4-DIHYDROXY-3,3-DIMETHYLBUTANAMIDE

(R)-N-(3-((2-AMINOETHYL)AMINO)-3-OXOPROPYL)-2,4-DIHYDROXY-3,3-DIMETHYLBUTANAMIDE

C11H23N3O4 (261.1688)


   

1-Piperidinecarboxylic acid, 3-hydroxy-4,4-dimethoxy-, 1,1-dimethylethyl ester

1-Piperidinecarboxylic acid, 3-hydroxy-4,4-dimethoxy-, 1,1-dimethylethyl ester

C12H23NO5 (261.1576)


   

octanal / methyl anthranilate schiffs base

octanal / methyl anthranilate schiffs base

C16H23NO2 (261.1729)


   

ethyl (1S,2S)-2-[(1S)-phenylethyl]aminocyclopentane-1-carboxylate

ethyl (1S,2S)-2-[(1S)-phenylethyl]aminocyclopentane-1-carboxylate

C16H23NO2 (261.1729)


   

propan-2-yl 1-methyl-4-phenylpiperidine-4-carboxylate

propan-2-yl 1-methyl-4-phenylpiperidine-4-carboxylate

C16H23NO2 (261.1729)


   

4-[1-(4,5-DIHYDRO-4,4-DIMETHYL-2-OXAZOLYL)-1-METHYLETHYL]-BENZENEETHANOL

4-[1-(4,5-DIHYDRO-4,4-DIMETHYL-2-OXAZOLYL)-1-METHYLETHYL]-BENZENEETHANOL

C16H23NO2 (261.1729)


   

boc-(2r,3r)-3-amino-2-hydroxy-5-methylhexanoic acid

boc-(2r,3r)-3-amino-2-hydroxy-5-methylhexanoic acid

C12H23NO5 (261.1576)


   

betaprodine

betaprodine

C16H23NO2 (261.1729)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent

   

ethoheptazine

ethoheptazine

C16H23NO2 (261.1729)


C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist

   

Etoxadrol

Etoxadrol

C16H23NO2 (261.1729)


C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent

   

3-Allyl-2-[2-(diethylamino)ethoxy]benzaldehyde

3-Allyl-2-[2-(diethylamino)ethoxy]benzaldehyde

C16H23NO2 (261.1729)


   

dl-alpha-Prodine

dl-alpha-Prodine

C16H23NO2 (261.1729)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Deoxy-PF-1140

Deoxy-PF-1140

C16H23NO2 (261.1729)


   

(3S)-3-[(3-hydroxypentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

(3S)-3-[(3-hydroxypentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO5 (261.1576)


   

2-Heptyl-3,4-dihydroxyquinoline

2-Heptyl-3,4-dihydroxyquinoline

C16H23NO2 (261.1729)


   

(R)-3-((3-Hydroxy-3-methylbutanoyl)oxy)-4-(trimethylammonio)butanoate

(R)-3-((3-Hydroxy-3-methylbutanoyl)oxy)-4-(trimethylammonio)butanoate

C12H23NO5 (261.1576)


   

2-Hydroxyisovalerylcarnitine

2-Hydroxyisovalerylcarnitine

C12H23NO5 (261.1576)


   

4-Hydroxyvalerylcarnitine

4-Hydroxyvalerylcarnitine

C12H23NO5 (261.1576)


   

Hydroxyvalerylcarnitine

Hydroxyvalerylcarnitine

C12H23NO5 (261.1576)


   

3-Hydroxy-3-[hydroxy-(trimethylazaniumyl)methyl]-6-methyl-4-oxoheptanoate

3-Hydroxy-3-[hydroxy-(trimethylazaniumyl)methyl]-6-methyl-4-oxoheptanoate

C12H23NO5 (261.1576)


   

2-hydroxypentanoyl-L-carnitine

2-hydroxypentanoyl-L-carnitine

C12H23NO5 (261.1576)


   

1-Benzyl-3-trimethylsilanyloxy-1,2,3,6-tetrahydropyridine

1-Benzyl-3-trimethylsilanyloxy-1,2,3,6-tetrahydropyridine

C15H23NOSi (261.1549)


   

HEXYLCAINE

HEXYLCAINE

C16H23NO2 (261.1729)


C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent

   

Bufuralol

(+/-)-bufuralol

C16H23NO2 (261.1729)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists Bufuralol (Ro 3-4787) is a potent non-selective, orally active β-adrenoreceptor antagonist with partial agonist activity. Bufuralol hydrochloride is a CYP2D6 probe substrate[1][2][3][4].

   

hydroxyisovaleroyl carnitine

hydroxyisovaleroyl carnitine

C12H23NO5 (261.1576)


   

Hydroxyisovaleroylcarnitine

3-(3-hydroxy-3-methylbutanoyl)oxy-4-(trimethylazaniumyl)butanoate

C12H23NO5 (261.1576)


An O-acylcarnitine having 3-hydroxyisovaleryl as the acyl substituent.

   

O-(3-hydroxyvaleryl)-L-carnitine

O-(3-hydroxyvaleryl)-L-carnitine

C12H23NO5 (261.1576)


An O-acyl-L-carnitine in which the acyl group is specified as 3-hydroxyvaleryl.

   

O-(hydroxyvaleryl)carnitine

O-(hydroxyvaleryl)carnitine

C12H23NO5 (261.1576)


An O-acylcarnitine having hydroxyvaleryl as the acyl substituent in which the position of the hydroxy group is unspecified.

   

O-hydroxyvaleroyl-L-carnitine

O-hydroxyvaleroyl-L-carnitine

C12H23NO5 (261.1576)


An O-acyl-L-carnitine in which the acyl group specified is hydroxyvaleroyl in which the position of the hydroxy group is unspecified.

   

CAR 4:0;2OH,3Me

CAR 4:0;2OH,3Me

C12H23NO5 (261.1576)


   

CAR 4:0;OH,Me

CAR 4:0;OH,Me

C12H23NO5 (261.1576)


   
   

(1s,2s,4ar,8as)-1-isothiocyanato-4a-methyl-8-methylidene-2-(prop-1-en-2-yl)-octahydronaphthalene

(1s,2s,4ar,8as)-1-isothiocyanato-4a-methyl-8-methylidene-2-(prop-1-en-2-yl)-octahydronaphthalene

C16H23NS (261.1551)


   

(1s,10s,13s,14r,15s)-14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

(1s,10s,13s,14r,15s)-14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

C16H23NO2 (261.1729)


   

(1r,2r,3r,5r,7r,7ar)-5-[(3s)-3-hydroxybutyl]-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2,7-triol

(1r,2r,3r,5r,7r,7ar)-5-[(3s)-3-hydroxybutyl]-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2,7-triol

C12H23NO5 (261.1576)


   

4-[(2s)-1-isopropyl-4-methyl-5,6-dihydro-2h-pyridin-2-yl]-5-methylbenzene-1,3-diol

4-[(2s)-1-isopropyl-4-methyl-5,6-dihydro-2h-pyridin-2-yl]-5-methylbenzene-1,3-diol

C16H23NO2 (261.1729)


   

(1s,4s,10s,13s,15r)-4-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

(1s,4s,10s,13s,15r)-4-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

C16H23NO2 (261.1729)


   

(6r,6as,8r,10s,10ar)-6,6a,8,10-tetramethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-ol

(6r,6as,8r,10s,10ar)-6,6a,8,10-tetramethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-ol

C16H23NO2 (261.1729)


   

n-(2-methylpropyl)-12-oxododeca-2,4,8,10-tetraenimidic acid

n-(2-methylpropyl)-12-oxododeca-2,4,8,10-tetraenimidic acid

C16H23NO2 (261.1729)


   

8-deoxy-13-dehydroserratinine

NA

C16H23NO2 (261.1729)


{"Ingredient_id": "HBIN013703","Ingredient_name": "8-deoxy-13-dehydroserratinine","Alias": "NA","Ingredient_formula": "C16H23NO2","Ingredient_Smile": "CC1CC2CC(=O)C3CCN4C3C2(CCC4)C(=O)C1","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "38592","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1s,2r,3r,5s,7ar)-5-(1,3-dihydroxybutyl)-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2-diol

(1s,2r,3r,5s,7ar)-5-(1,3-dihydroxybutyl)-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2-diol

C12H23NO5 (261.1576)


   

(1s,8ar)-4-isopropyl-1-isothiocyanato-1,6-dimethyl-3,7,8,8a-tetrahydro-2h-naphthalene

(1s,8ar)-4-isopropyl-1-isothiocyanato-1,6-dimethyl-3,7,8,8a-tetrahydro-2h-naphthalene

C16H23NS (261.1551)


   

(4s,6s)-6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-1(13)-ene-2,8-dione

(4s,6s)-6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-1(13)-ene-2,8-dione

C16H23NO2 (261.1729)


   

(1s,10s,13s,14s,15s)-14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

(1s,10s,13s,14s,15s)-14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

C16H23NO2 (261.1729)


   

(2r,4as,11ar,13as)-2-methyl-decahydro-1h-indeno[3a,3-i]indolizine-4,12-dione

(2r,4as,11ar,13as)-2-methyl-decahydro-1h-indeno[3a,3-i]indolizine-4,12-dione

C16H23NO2 (261.1729)


   

(1r,9s,11s,13s,14r)-9,11,13,14-tetramethyl-8-oxa-6-azatricyclo[7.4.1.0²,⁷]tetradeca-2,4,6-trien-3-ol

(1r,9s,11s,13s,14r)-9,11,13,14-tetramethyl-8-oxa-6-azatricyclo[7.4.1.0²,⁷]tetradeca-2,4,6-trien-3-ol

C16H23NO2 (261.1729)


   

(1r,2s,4r,6s,9s)-2-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-15-en-8-one

(1r,2s,4r,6s,9s)-2-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-15-en-8-one

C16H23NO2 (261.1729)


   

14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

C16H23NO2 (261.1729)


   

(4r,6r)-6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-1(13)-ene-2,8-dione

(4r,6r)-6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-1(13)-ene-2,8-dione

C16H23NO2 (261.1729)


   

(1r,2r,10s,12s,13r)-12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

(1r,2r,10s,12s,13r)-12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

C16H23NO2 (261.1729)


   

5-(3-hydroxybutyl)-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2,7-triol

5-(3-hydroxybutyl)-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2,7-triol

C12H23NO5 (261.1576)


   

(1s,2r,3r,5s,7ar)-5-[(1r,3s)-1,3-dihydroxybutyl]-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2-diol

(1s,2r,3r,5s,7ar)-5-[(1r,3s)-1,3-dihydroxybutyl]-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2-diol

C12H23NO5 (261.1576)


   

(1s,10s,12s,13r,15r)-12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

(1s,10s,12s,13r,15r)-12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

C16H23NO2 (261.1729)


   

3-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

3-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

C16H23NO2 (261.1729)


   

9,11,13,14-tetramethyl-8-oxa-4-azatricyclo[7.4.1.0²,⁷]tetradeca-2(7),3,5-trien-3-ol

9,11,13,14-tetramethyl-8-oxa-4-azatricyclo[7.4.1.0²,⁷]tetradeca-2(7),3,5-trien-3-ol

C16H23NO2 (261.1729)


   

9,11,13,14-tetramethyl-8-oxa-6-azatricyclo[7.4.1.0²,⁷]tetradeca-2,4,6-trien-3-ol

9,11,13,14-tetramethyl-8-oxa-6-azatricyclo[7.4.1.0²,⁷]tetradeca-2,4,6-trien-3-ol

C16H23NO2 (261.1729)


   

(1r,2r,13r,15r)-11-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-10-en-12-one

(1r,2r,13r,15r)-11-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-10-en-12-one

C16H23NO2 (261.1729)


   

(1r,4r,5s,6r,9s)-5-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-2-en-8-one

(1r,4r,5s,6r,9s)-5-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-2-en-8-one

C16H23NO2 (261.1729)


   

11-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-10-en-12-one

11-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-10-en-12-one

C16H23NO2 (261.1729)


   

(2e,4e,8e,10e)-n-(2-methylpropyl)-12-oxododeca-2,4,8,10-tetraenimidic acid

(2e,4e,8e,10e)-n-(2-methylpropyl)-12-oxododeca-2,4,8,10-tetraenimidic acid

C16H23NO2 (261.1729)


   

(4s,6r)-6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-1(13)-ene-2,8-dione

(4s,6r)-6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-1(13)-ene-2,8-dione

C16H23NO2 (261.1729)


   

(1r,2r,3r,5r,7r,7ar)-5-(3-hydroxybutyl)-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2,7-triol

(1r,2r,3r,5r,7r,7ar)-5-(3-hydroxybutyl)-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2,7-triol

C12H23NO5 (261.1576)


   

(1s,10s,13r,15s)-13-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

(1s,10s,13r,15s)-13-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

C16H23NO2 (261.1729)


   

(1r,2r,3s,10s,13s)-3-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

(1r,2r,3s,10s,13s)-3-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

C16H23NO2 (261.1729)


   

12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

C16H23NO2 (261.1729)


   

(1s,6r)-6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-4(13)-ene-2,8-dione

(1s,6r)-6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-4(13)-ene-2,8-dione

C16H23NO2 (261.1729)


   

6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-1(13)-ene-2,8-dione

6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-1(13)-ene-2,8-dione

C16H23NO2 (261.1729)


   

(1r,2s,4r,9s)-2-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-6-en-8-one

(1r,2s,4r,9s)-2-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-6-en-8-one

C16H23NO2 (261.1729)


   

(5s,6r)-6-[(8r,8as)-octahydroindolizine-8-carbonyl]-5-methylcyclohex-2-en-1-one

(5s,6r)-6-[(8r,8as)-octahydroindolizine-8-carbonyl]-5-methylcyclohex-2-en-1-one

C16H23NO2 (261.1729)


   

4-isopropyl-1-isothiocyanato-1,6-dimethyl-3,7,8,8a-tetrahydro-2h-naphthalene

4-isopropyl-1-isothiocyanato-1,6-dimethyl-3,7,8,8a-tetrahydro-2h-naphthalene

C16H23NS (261.1551)


   

6,6a,8,10-tetramethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-ol

6,6a,8,10-tetramethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-ol

C16H23NO2 (261.1729)


   

11-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-14-one

11-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-14-one

C16H23NO2 (261.1729)


   

4-[2-(dimethylamino)ethyl]-4-(4-hydroxyphenyl)cyclohexan-1-one

4-[2-(dimethylamino)ethyl]-4-(4-hydroxyphenyl)cyclohexan-1-one

C16H23NO2 (261.1729)


   

(1r,2r,10r,12s,13r)-12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

(1r,2r,10r,12s,13r)-12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

C16H23NO2 (261.1729)


   

(1r,2r,3s,10s)-3-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

(1r,2r,3s,10s)-3-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

C16H23NO2 (261.1729)


   

5-(1,3-dihydroxybutyl)-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2-diol

5-(1,3-dihydroxybutyl)-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2-diol

C12H23NO5 (261.1576)


   

(1s,10s,13r)-13-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

(1s,10s,13r)-13-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-one

C16H23NO2 (261.1729)


   

(1r,6r)-6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-4(13)-ene-2,8-dione

(1r,6r)-6-methyl-9-azatricyclo[7.4.3.0⁴,¹³]hexadec-4(13)-ene-2,8-dione

C16H23NO2 (261.1729)


   

(1r,2r,4s,10r,11s,13s,15r)-11-hydroxy-15-methyl-6-azapentacyclo[8.6.0.0¹,⁶.0²,¹³.0⁴,¹⁰]hexadecan-8-one

(1r,2r,4s,10r,11s,13s,15r)-11-hydroxy-15-methyl-6-azapentacyclo[8.6.0.0¹,⁶.0²,¹³.0⁴,¹⁰]hexadecan-8-one

C16H23NO2 (261.1729)


   

(1r,9s,11s,13s,14r)-9,11,13,14-tetramethyl-8-oxa-4-azatricyclo[7.4.1.0²,⁷]tetradeca-2(7),3,5-trien-3-ol

(1r,9s,11s,13s,14r)-9,11,13,14-tetramethyl-8-oxa-4-azatricyclo[7.4.1.0²,⁷]tetradeca-2(7),3,5-trien-3-ol

C16H23NO2 (261.1729)


   

4-(4-methoxyphenyl)-1-[(2r)-piperidin-2-yl]butan-2-one

4-(4-methoxyphenyl)-1-[(2r)-piperidin-2-yl]butan-2-one

C16H23NO2 (261.1729)


   

12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

12-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-14-en-11-one

C16H23NO2 (261.1729)


   

1-isothiocyanato-4a-methyl-8-methylidene-2-(prop-1-en-2-yl)-octahydronaphthalene

1-isothiocyanato-4a-methyl-8-methylidene-2-(prop-1-en-2-yl)-octahydronaphthalene

C16H23NS (261.1551)


   

(1s,2r,4s,6s)-2-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-9-en-8-one

(1s,2r,4s,6s)-2-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-9-en-8-one

C16H23NO2 (261.1729)


   

11-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-2-en-8-one

11-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-2-en-8-one

C16H23NO2 (261.1729)


   

(1r,4r,9s)-2-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-6-en-8-one

(1r,4r,9s)-2-hydroxy-4-methyl-13-azatetracyclo[7.7.0.0¹,⁶.0²,¹³]hexadec-6-en-8-one

C16H23NO2 (261.1729)